Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4811123 | 1.00 | GSK3B (0.32) | GSK3BTSHRTRPA1 | |
| SCHEMBL10743466 | 1.00 | GSK3B (0.32) | GSK3BTSHRTRPA1 | |
| Hydrochloric Acid SCHEMBL4812022 | 0.98 | GSK3B (0.32) | GSK3BTSHR | |
| SCHEMBL28455957 | 0.81 | TSHR (0.31) | TSHR | |
| Hydrochloric Acid SCHEMBL4806937 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL4812908 | 0.81 | — | — | |
| SCHEMBL4812019 | 0.81 | GSK3B (0.32) | GSK3B | |
| SCHEMBL9651049 | 0.81 | GSK3B (0.32) | GSK3B | |
| SCHEMBL9651149 | 0.81 | GSK3B (0.32) | GSK3B | |
| SCHEMBL9651052 | 0.81 | GSK3B (0.32) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020028931-A1 | Ceftiofur, its intermediate and a process for the preparation of the same | AUROBINDO PHARMA LIMITED (IN) | 2002-03-07 | — | — | US | claimed |
| US-4205180-A | CHEMICAL INTERMEDIATES FOR NOVEL CEPHALOSPORIN COMPOUNDS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1980-05-27 | — | — | US | claimed |
| JP-55094354-A | — | — | None | — | — | JP | disclosed |
| US-7470786-B2 | Method for manufacture of ceftriaxone sodium | LUPIN LIMITED (IN) | 2008-12-30 | — | — | US | disclosed |
| US-20080200670-A1 | METHOD FOR THE MANUFACTURE OF CEFTRIAXONE SODIUM | LUPIN LIMITED (RESEARCH PARK) (IN) | 2008-08-21 | — | — | US | disclosed |
| US-20070049749-A1 | Method for Manufacture of Ceftriaxone Sodium | LUPIN LIMITED (RESEARCH PARK) (IN) | 2007-03-01 | — | — | US | disclosed |
| US-20070015917-A1 | Method For Manufacture of Ceftriaxone Sodium | LUPIN LIMITED (RESEARCH PARK) (IN) | 2007-01-18 | — | — | US | disclosed |
| WO-2006067803-A1 | A NOVEL INTERMEDIATE FOR THE PREPARATION OF CEFEPIME | LUPIN LIMITED (IN) | 2006-06-29 | — | — | WO | disclosed |
| WO-2005040175-A2 | PROCESS FOR THE PREPARATION OF CEPHEM CARBOXYLIC ACIDS | RANBAXY LABORATORIES LIMITED (IN) | 2005-05-06 | — | — | WO | disclosed |
| US-20050059821-A1 | Method for manufacture of ceftriaxone sodium | DATTA DEBASHISH (IN) | 2005-03-17 | — | — | US | disclosed |
| US-20050059820-A1 | Method for manufacture of ceftriaxone sodium | LUPIN LIMITED (IN) | 2005-03-17 | — | — | US | disclosed |
| US-4489072-A | BACTERICIDE, ANTIBIOTIC | TOYAMA CHEMICAL CO., LTD. (JP) | 1984-12-18 | — | — | US | disclosed |
| US-4487927-A | BACTERICIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-12-11 | — | — | US | disclosed |
| EP-0036510-B1 | SYNISOMER CEPHALOSPORIN COMPOUNDS AND PROCESSES FOR THEIR PREPARATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-11-21 | — | — | EP | disclosed |
| EP-0123024-A2 | 7-Acylamino-3-vinylcephalosporanic acid derivatives, processes for their preparation, pharmaceutical compositions containing them; their starting compounds and their preparation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-10-31 | — | — | EP | disclosed |
| US-4458072-A | CEPHALOSPORIN AND OXACEPHALOSPORIN BACTERICIDES | HOFFMANN-LA ROCHE INC. (US) | 1984-07-03 | — | — | US | disclosed |
| US-4423213-A | ANTIBIOTIC | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-12-27 | — | — | US | disclosed |
| US-4409214-A | Including cefixime; antibiotics | FUJISAWA PHARMACEUTICAL, CO., LTD. (JP) | 1983-10-11 | — | — | US | disclosed |
| EP-0030630-A2 | 7-Acylamino-3-vinylcephalosporanic acid derivatives, processes for their preparation, pharmaceutical compositions containing them; their starting compounds and their preparation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-06-24 | — | — | EP | disclosed |
| JP-S5594354-A | SYN-ISOMER OF 2-SUBSTITUTED IMINO-3-OXO-4-HALOBUTYRIC ACID, ITS SALT, AND THEIR PREPARATION | FUJISAWA PHARMACEUT CO LTD | 1980-07-17 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049749-A1 | Method for Manufacture of Ceftriaxone Sodium | TREH, CHAT, MRPL21 | GSK3B 841/4885TSHR 3097/4885TRPA1 4857/4885 |
| US-20020028931-A1 | Ceftiofur, its intermediate and a process for the preparation of the same | BLVRB, CBR1, BTD | GSK3B 2672/4885TSHR 510/4885TRPA1 4866/4885 |
| US-20050059820-A1 | Method for manufacture of ceftriaxone sodium | TREH, CHAT, MRPL21 | GSK3B 841/4885TSHR 3097/4885TRPA1 4857/4885 |
| US-20070015917-A1 | Method For Manufacture of Ceftriaxone Sodium | TREH, CHAT, MRPL21 | GSK3B 841/4885TSHR 3097/4885TRPA1 4857/4885 |
| US-20080200670-A1 | METHOD FOR THE MANUFACTURE OF CEFTRIAXONE SODIUM | CHAT, TREH, MRPL21 | GSK3B 702/4885TSHR 3037/4885TRPA1 4855/4885 |
| US-20050059821-A1 | Method for manufacture of ceftriaxone sodium | TREH, CHAT, MRPL21 | GSK3B 841/4885TSHR 3097/4885TRPA1 4857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.